이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Korea’s ATGen receives approval of immunoassay kit in Indonesia

Collected: 2018.01.25

Distributed: 2018.01.26

Source: Go Direct

[Photo provided by ATGen]

ATGen, a South Korean manufacturer of diagnosis reagents and kits, said on Wednesday that Indonesian health authorities (Department Kesehatan) have granted marketing approval to its immunoassay kit NK Vue Kit.

The diagnosis kit measures the activity of plasma NK (natural killer) cells to help diagnose cancer or other serious health conditions.

NK cells are lymphocytes of the innate immune system that are involved in early defense mechanisms against foreign pathogenic agents.

At 11:40 am on Thursday, Kosdaq-listed ATGen shares were up 1.74 percent at 23,450 won ($22.08).

In 2016, ATGen signed a contract with a Royal Sumatra Group company to distribute the kits across Indonesia. Royal Sumatra Group runs golf courses and is involved in defense, resource development and healthcare businesses in the world’s fourth most populated country.

Indonesia’s medical device market is on a steady growth curve and health expenditures have kept rising since 2014 when a new health program was launched to improve healthcare access for low-income households.

Earlier this year, ATGen received marketing approval of NK Vue Kit from the Kazakh government.

By Kim Hye-soon and Minu Kim

List

Previous: Korea’s Nonghyup Financial, Vietnam’s Agribank offer joint wire svc

Next: S. Korea’s exports of petrochemical products reach all-time high in 2017